Gaithersburg-based MedImmune drug advances
Daily Record, The (Baltimore), Apr 16, 2008
MedImmune Inc., of Gaithersburg, a biotechnology company focused on developing and manufacturing products to combat infectious disease, autoimmune disease and cancer, announced the start of two new clinical trials as part of its efforts to develop CAT-354, an antibody that MedImmune sees as a potential treatment for patients with asthma.
One of the studies is a Phase 2 clinical trial in Europe and Australia designed to assess the potential of the antibody in patients with uncontrolled asthma despite optimal treatment. The company has also begun dosing patients in the first U.S.-based clinical trial of the antibody, a Phase 1 study to assess the antibody's effects in healthy adult patients.
Most Recent Business Articles
- Multiple criteria evaluation and optimization of transportation systems
- Multi-criteria analysis procedure for sustainable mobility evaluation in urban areas
- A two-leveled multi-objective symbiotic evolutionary algorithm for the hub and spoke location problem
- Multi-criteria analysis for evaluating the impacts of intelligent speed adaptation
- The development of Taiwan arterial traffic-adaptive signal control system and its field test: a Taiwan experience
Most Recent Business Publications
Most Popular Business Articles
- 7 tips for effective listening: productive listening does not occur naturally. It requires hard work and practice - Back To Basics - effective listening is a crucial skill for internal auditors
- FAS 109: a primer for non-accountants - Financial Accounting Standards Board's "Statement 109: Accounting for Income Taxes"
- Design a commission plan that drives sales - Sales Commissions
- Too Young to Rent a Car? - 25-years-old the minimum age for car renting - Brief Article
- LIFO vs. FIFO: a return to the basics
Most Popular Business Publications
Content provided in partnership with
